Titre :

Improved outcome in children compared to adolescents and young adults after allogeneic hematopoietic stem cell transplant for acute myeloid leukemia: a retrospective study from the Francophone Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC).

Auteur(s) :

Pochon, Cécile [Auteur]
Service d'Oncologie Pédiatrique [CHRU Nancy]
Detrait, Marie [Auteur]
Service d'Hématologie [CHRU Nancy]
Ingénierie Moléculaire et Physiopathologie Articulaire [IMoPA]
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Dalle, Jean-Hugues [Auteur]
Unité d'Hémato-Immunologie pédiatrique [Hôpital Robert Debré, Paris]
Hôpital Robert Debré Paris
Michel, Gérard [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
Dhédin, Nathalie [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Chalandon, Yves [Auteur]
Geneva University Hospitals and Geneva University
Brissot, Eolia [Auteur]
Centre de Recherche Saint-Antoine [CRSA]
CHU Saint-Antoine [AP-HP]
Forcade, Edouard [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Sirvent, Anne [Auteur]

Izzadifar-Legrand, Faezeh [Auteur]
Institut Paoli-Calmettes [IPC]
Michallet, Mauricette [Auteur]
Centre Léon Bérard [Lyon]
Renard, Cécile [Auteur]
Institut d'hématologie et d'oncologie pédiatrique [CHU - HCL] [IHOPe]
Hospices Civils de Lyon [HCL]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Gonzales, Fanny [Auteur]
Bay, Jacques-Olivier [Auteur]
Service Hématologie Biologique [CHU Clermont-Ferrand]
CHU Clermont-Ferrand
Kanold, Justyna [Auteur]
Cornillon, Jérome [Auteur]
Institut de Cancérologie et d'Hématologie Universitaire de Saint-Étienne [CHU Saint-Etienne] [ICHUSE]
Bulabois, Claude Eric [Auteur]
Centre Hospitalier Universitaire [CHU Grenoble] [CHUGA]
Angoso, Marie [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Nguyen, Stephanie [Auteur]
Centre d'Immunologie et des Maladies Infectieuses [CIMI]
CHU Pitié-Salpêtrière [AP-HP]
Balza, M. [Auteur]
Chevallier, P. [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Rialland, F. [Auteur]
Bazarbachi, A. [Auteur]
Beguin, Y. [Auteur]
Huynh, A. [Auteur]
Pôle IUCT [CHU Toulouse]
Ménard, A. L. [Auteur]
Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen [CLCC Henri Becquerel]
Schneider, P. [Auteur]
Neven, B. [Auteur]
Hôpital Necker - Enfants Malades [AP-HP]
Service d'immuno-hématologie pédiatrique [CHU Necker]
Paillard, C. [Auteur]
Hôpital de Hautepierre [Strasbourg]
Raus, N. [Auteur]
Albuisson, E. [Auteur]
Remen, T. [Auteur]
Centre Hospitalier Régional Universitaire de Nancy [CHRU Nancy]
Délégation à la Recherche Clinique et à l'Innovation [CHRU Nancy] [DRCI]
Rubio, M. T. [Auteur]
Service d'Hématologie [CHRU Nancy]
Ingénierie Moléculaire et Physiopathologie Articulaire [IMoPA]

Titre de la revue :

Journal of Cancer Research and Clinical Oncology

Nom court de la revue :

J Cancer Res Clin Oncol

Date de publication :

2021-09-05

ISSN :

1432-1335

Mot(s)-clé(s) en anglais :

Acute myeloblastic leukemia
Allogeneic hematopoietic stem cell transplantation
Children
Adolescent and post-adolescent patients
Young adults
Outcome
Acute GVHD
Chronic GVHD

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Background There are currently few data on the outcome of acute myeloid leukemia (AML) in adolescents after allogeneic HSCT. The aim of this study is to describe the outcome and its specific risk factors for children, ...
Lire la suite >Background There are currently few data on the outcome of acute myeloid leukemia (AML) in adolescents after allogeneic HSCT. The aim of this study is to describe the outcome and its specific risk factors for children, adolescents and young adults after a first allogeneic HSCT for AML. Methods In this retrospective study, we compared the outcome of AML patients receiving a first allogeneic HSCT between 2005 and 2017 according to their age at transplantation’s time: children (< 15 years, n = 564), adolescent and post-adolescent (APA) patients (15–25 years, n = 647) and young adults (26–40 years; n = 1434). Results With a median follow-up of 4.37 years (min–max 0.18–14.73 years), the probability of 2-year overall survival (OS) was 71.4% in children, 61.1% in APA patients and 62.9% in young adults (p = 0.0009 for intergroup difference). Both relapse and non-relapse mortality (NRM) Cumulative Incidence (CI) estimated at 2 years were different between the age groups (30.8% for children, 35.2% for APA patients and 29.4% for young adults—p = 0.0254, and 7.0% for children, 10.6% for APA patients and 14.2% for young adults, p < 0.0001; respectively). Whilst there was no difference between the three groups for grade I to IV acute GVHD CI at 3 months, the chronic GVHD CI at 2 years was higher in APA patients and young adults (31.4% and 36.4%, respectively) in comparison to the children (17.5%) (p < 0.0001). In multivariable analysis, factors associated with death were AML cytogenetics (HR1.73 [1.29–2.32] for intermediate risk 1, HR 1.50 [1.13–2.01] for intermediate risk 2, HR 2.22 [1.70–2.89] for high cytogenetics risk compared to low risk), use of TBI ≥ 8 Grays (HR 1.33 [1.09–1.61]), disease status at transplant (HR 1.40 [1.10–1.78] for second Complete Remission (CR), HR 2.26 [1.02–4.98] for third CR and HR 3.07 [2.44–3.85] for active disease, compared to first CR), graft source (HR 1.26 [1.05–1.50] for Peripheral Blood Stem Cells compared to Bone Marrow) and donor age (HR 1.01 (1–1.02] by increase of 1 year). Conclusion Age is an independent risk factor for NRM and extensive chronic GVHD. This study suggests that APA patients with AML could be beneficially treated with a chemotherapy-based MAC regimen and bone marrow as a stem cells source.Lire moins >

Langue :

Anglais

Comité de lecture :

Oui

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-01-12T06:05:49Z
2024-02-27T12:33:31Z